Skip to content

Study · Not a test of the peptide alone · 2011

2 results

GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells.

Siejka A, Barabutis N, Schally AV

Cell cycle (Georgetown, Tex.)1 Nov 2011Cited by 24 (Europe PMC)

PMID22041656 (opens in a new tab)DOI10.4161/cc.10.21.17904 (opens in a new tab)PepBankPUB-22041656
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism

    In A549 lung cancer cells, GHRH(1-29)NH2 counteracted the effects of the GHRH antagonist MZ-5-156 on proliferation, AMPK, GSK3β, Akt, mTOR and eIF4E.

    In plain wordsIn cells, GHRH(1-29)NH2 reversed the effects that a GHRH blocking drug had on lung cancer cell growth pathways.

    Peptide
    Sermorelin
    Outcome
    Not applicableReversal of GHRH antagonist effects in A549 cells
    Study

    humann: not reported in source

    A549 non-small cell lung cancer cells
    Comparator
    MZ-5-156
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    GHRH(1-29)NH2 counteracted all these effects.
    1 context sentence
    Summary · context
    Treatment of A549 cells with GHRH antagonist decreased cell proliferation and activated AMPK as well as glycogen synthase kinase (GSK)3β. Furthermore, MZ-5-156 inhibited Akt, the mammalian target of rapamycin (mTOR) and its downstream target eIF4E which controls protein synthesis and cell growth.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism

    In HeLa cells that do not express GHRH receptors, GHRH did not induce AMPK activation.

    In plain wordsIn cells without GHRH receptors, GHRH did not switch on AMPK.

    Peptide
    Sermorelin
    Outcome
    No significant changeAMPK activation by GHRH in HeLa cells lacking GHRH receptors
    Study

    humann: not reported in source

    HeLa cells without GHRH receptors
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    HeLa human endometrial cancer cells which do not express any GHRH receptors were used as a negative control and GHRH did not induce the AMPK activation in these cells.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.